Cartesian Therapeutics’ Descartes-08 Gains the US FDA’s RMAT Designation to Treat Myasthenia Gravis
Shots:
- The US FDA has granted RMAT designation to descartes-08 for treating myasthenia gravis (MG). It has also been designated with the FDA’s ODD for the same indication
- The company reported 12mos. follow-up data in Jan 2024 from its P-IIa study. Descartes-08 showed durable autoantibody depletion and improved MG severity scores with a well-tolerated safety profile & without DLTs, cytokine release syndrome or neurotoxicity at 1mos. follow-up period. Topline P-IIb data is anticipated in mid-2024
- Descartes-08, an autologous mRNA CAR-T, works by targeting BCMA and is being developed for MG which is a chronic autoimmune disorder causing muscle weakness and fatigue
Ref: Cartesian Therapeutics | Image: Cartesian Therapeutics
Related Posts:- Johnson & Johnson Reports the Results from 2 Trials of Nipocalimab to Treat Generalized Myasthenia Gravis (gMG) and Sjögren’s Disease (SjD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
